The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
NCRI 2016 | Perspective on immune modulation to fight cancer
Lieping Chen, MD, PhD of Yale School of Medicine, New Haven, CT discusses two approaches to cancer immunotherapy. Immune system activation approach aims to push the immune system to the limit, but this may result in toxicities before treatment efficacy is reached. The alternative approach, as shown in the PD-1/PD-L1 study, is to regulate the immune system response to the normal level, which offers lower toxicity levels compared to other treatments like chemotherapy. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.
